Home › Markets › Health Care › AMRX

Amneal Pharmaceuticals Inc. (AMRX)

AMRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$19.57
-2.30% on the day
Market cap
$6.8B
Mid cap
Revenue · 2025
$3.0B
+8.0% on 2024
Net income · 2025
$72.1M
2.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerAMRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001723128
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$3.0B
Net income$72.1M
Operating income$394.1M
Net margin2.4%
Operating margin13.1%
Revenue growth+8.0%
Cash$282.0M
Total assets$3.7B
P/E (computed)94.6×
P/S (computed)2.3×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-09-03
Latest annual report10-K2026-02-27
Latest quarterly / interim10-Q2026-08-06
Latest current report8-K2026-08-10
Latest proxyDEFA14A2026-07-30

Source: SEC EDGAR submissions feed, 692 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.4%
1 month+15.2%
3 months+6.3%
Year to date+52.2%
1 year+96.7%
From 52-week high-6.4%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PRAXPraxis Precision Medicines Inc.$243.34-3.20%$6.8B
ALKSAlkermes plc$39.73-1.32%$6.7B
IONSIonis Pharmaceuticals Inc.$42.38-2.95%$7.0B
SYRESpyre Therapeutics Inc.$80.45-6.34%$7.1B
ABVXAbivax SA$86.22-0.83%$7.5B
KNSAKiniksa Pharmaceuticals International plc$78.53-0.90%$6.1B
BLTEBelite Bio Inc$151.87-4.24%$6.1B
LGNDLigand Pharmaceuticals Incorporated$303.53-2.44%$6.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier